Brenus Pharma Secures €11 Million Series A Extension to Advance Lead Cancer Immunotherapy and Expand Proprietary In Vivo Immunotherapy Platform
Brenus Pharma has announced the successful completion of an €11 million ($12.6 million) extension to its Series A financing round, further strengthening the company’s position as it advances its lead immunotherapy candidate through clinical development while expanding its proprietary in vivo immunotherapy platform. With the latest investment, the biotechnology company has now raised a total of €38 million ($43.5 million) since its inception, providing significant financial resources to support its clinical, regulatory, and research objectives.
The new financing reflects investor confidence in Brenus Pharma’s progress across multiple areas, including clinical development, regulatory advancement, and strategic business execution. According to the company, these achievements have helped reduce development risk surrounding STC-1010, its lead clinical-stage immunotherapy candidate currently being evaluated for the treatment of microsatellite stable metastatic colorectal cancer (MSS mCRC). At the same time, the funding positions Brenus to broaden the application of its proprietary technology platform by advancing additional therapeutic candidates into development.
The financing round attracted continued backing from several existing investors while also bringing new international institutional investors into the company’s shareholder base. This expanded investor support highlights growing global interest in innovative immunotherapy approaches designed to address cancers that remain difficult to treat using current therapeutic options.
Strengthening Financial Resources for Clinical Development
The €11 million Series A extension provides Brenus Pharma with additional capital to accelerate key milestones across its development pipeline.
The company plans to use the proceeds primarily to:
- Complete the ongoing Phase I clinical program for STC-1010.
- Continue advancing its proprietary in vivo immunotherapy platform.
- Progress the development of its next therapeutic candidate.
- Support broader platform expansion and future pipeline growth.
By securing additional financing while its lead program advances through early-stage clinical evaluation, Brenus aims to maintain development momentum while preparing for subsequent stages of clinical research.
The investment also provides greater operational flexibility as the company continues building a diversified immunotherapy portfolio.
Advancing STC-1010 for Colorectal Cancer
At the center of Brenus Pharma’s development strategy is STC-1010, the company’s lead investigational immunotherapy.
The candidate is currently being evaluated in the Phase I clinical study (NCT06934538) for patients with microsatellite stable metastatic colorectal cancer (MSS mCRC).
Metastatic colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and patients with the microsatellite stable subtype often have limited treatment options.
Unlike microsatellite instability-high (MSI-H) tumors, which have demonstrated responsiveness to certain immunotherapies, MSS colorectal cancers generally respond poorly to currently available immune checkpoint inhibitors.
This significant therapeutic challenge has driven continued research into new immunotherapy approaches capable of overcoming immune resistance in MSS disease.
Brenus believes STC-1010 may offer a differentiated strategy for stimulating anti-tumor immune responses in this underserved patient population.
Addressing a Significant Unmet Medical Need
Microsatellite stable metastatic colorectal cancer accounts for the majority of advanced colorectal cancer cases.
Although chemotherapy, targeted therapies, and combination treatment strategies have improved survival for many patients, long-term outcomes remain limited for individuals whose disease progresses despite standard treatment.
One of the primary challenges has been the limited effectiveness of conventional immunotherapies in MSS tumors.
Researchers continue to investigate innovative methods capable of enhancing immune recognition of cancer cells and generating stronger anti-tumor immune responses.
Brenus Pharma’s development program seeks to address this unmet need through a novel in vivo immunotherapy approach that differs from existing treatment strategies.
If successful, STC-1010 could expand immunotherapy options for a patient population that currently has relatively few effective immune-based treatments available.
Proprietary In Vivo Immunotherapy Platform
Beyond STC-1010, Brenus Pharma is developing a broader proprietary platform intended to generate multiple therapeutic candidates.
Rather than focusing on a single product, the company is investing in technology capable of supporting the development of numerous immunotherapies targeting different cancers.
The latest financing will help accelerate work on this platform while enabling advancement of additional drug candidates beyond STC-1010.
By establishing a multi-asset pipeline, Brenus aims to leverage its underlying technology across multiple oncology indications while reducing dependence on a single clinical program.
This strategy reflects a growing trend among biotechnology companies to build platform technologies capable of generating multiple therapeutic opportunities over time.
Clinical and Regulatory Progress Builds Investor Confidence
According to Brenus Pharma, the successful financing reflects the company’s execution across several critical operational areas.
Since its previous financing activities, the company has achieved progress in:
- Clinical development
- Regulatory interactions
- Business development
- Platform advancement
These accomplishments have helped reduce perceived development risk surrounding STC-1010 while increasing confidence in the company’s broader scientific strategy.
Early execution against clinical and operational milestones often plays an important role in attracting continued investor support within the biotechnology sector, particularly for companies developing first-in-class therapeutic platforms.
Strong Continued Support from Existing Investors
The financing round included substantial follow-on investment from Brenus Pharma’s existing shareholder base.
Returning investors include:
- Angelor
- UI Investissement (managing FRAI)
- Crédit Agricole through CACE Création and CACF Capital Innovation
- Noshaq
- Orsa (formerly Investsud)
- BIO JAG
- Bpifrance through non-dilutive funding
The continued participation of these investors demonstrates sustained confidence in the company’s management team, scientific platform, and clinical development strategy.
Follow-on investment from existing shareholders is often viewed as an important indicator of confidence in a company’s long-term prospects.
Expanding International Investor Participation
In addition to continued support from existing investors, Brenus Pharma welcomed two new institutional investors to its shareholder group.
These additions further strengthen the company’s international financing network and broaden its geographic investor base.
The new investors include:
- Sambrinvest, which expands Brenus Pharma’s European investor representation.
- Korea Omega Investment Corp, marking the company’s first institutional investment from the Asia-Pacific region.
The participation of international investors reflects growing global interest in innovative oncology platforms and demonstrates the increasing visibility of Brenus Pharma beyond its domestic market.
Korea Omega Investment Highlights European Innovation
Commenting on the investment, Dae Kyeong Bae, Senior Vice President at Korea Omega Investment Corp, expressed confidence in Brenus Pharma’s scientific platform and development progress.
He described the investment as the firm’s first in France and emphasized that Brenus combines differentiated technology with encouraging early clinical validation and an experienced management team capable of executing efficiently.
According to Bae, these characteristics align well with Korea Omega Investment Corp’s strategy of expanding its international portfolio by supporting promising European biotechnology companies.
He also noted the firm’s enthusiasm for supporting Brenus as it advances innovative therapies intended to address significant unmet medical needs among cancer patients.
Company Leadership Outlines Next Development Phase
Paul Bravetti, Chief Executive Officer of Brenus Pharma, welcomed both the continued commitment of existing investors and the addition of new international shareholders.
He stated that the financing will enable the company to complete the ongoing Phase I clinical program while continuing development of its proprietary in vivo immunotherapy platform.
Bravetti also indicated that Brenus intends to use the funding to advance its next investigational drug candidate, expanding the company’s pipeline beyond STC-1010.
In addition, he expressed appreciation for the long-term support provided by Brenus Pharma’s historical investors, whose continued confidence has contributed significantly to the company’s growth and scientific progress.
Building a Multi-Asset Oncology Company
The latest financing positions Brenus Pharma to continue evolving from a single-asset biotechnology company into a broader oncology platform organization.
As clinical data become available from STC-1010, the company plans to leverage insights gained from its lead program to accelerate additional therapeutic candidates generated through its proprietary platform.
Developing multiple assets may enable Brenus to address several cancer indications while creating opportunities for future strategic partnerships and expanded clinical development.
This diversified approach has become increasingly common among emerging biotechnology companies seeking long-term growth through platform innovation.
The successful completion of the €11 million Series A extension represents an important milestone in Brenus Pharma’s evolution as a clinical-stage oncology company. By increasing its total funding to €38 million since inception, the company has strengthened its financial foundation to support completion of the Phase I clinical evaluation of STC-1010 while accelerating development of its proprietary in vivo immunotherapy platform. Continued support from existing investors, combined with the addition of new institutional partners from Europe and the Asia-Pacific region, reflects growing confidence in Brenus Pharma’s scientific strategy and execution capabilities.
As the company advances STC-1010 for patients with microsatellite stable metastatic colorectal cancer and expands its pipeline with additional immunotherapy candidates, it aims to address significant unmet needs in oncology through innovative immune-based treatment approaches. The new financing provides Brenus Pharma with the resources to pursue both near-term clinical milestones and longer-term platform expansion, positioning the company for continued growth as it works to develop next-generation therapies for patients facing difficult-to-treat cancers.
About Brenus Pharma
Brenus Pharma develops an off-the-shelf platform advancing novel modalities in immuno-oncology. This cutting-edge precision technology mimics tumor protein expression and makes it visible to the immune system, enabling a multi-specific in vivo immune response adapting to tumor evolution in hard-to-treat solid tumors, where current therapies fall short.